Orquest
This article was originally published in The Gray Sheet
Executive Summary
Clinical studies of firm's Ossigel bone growth factor will begin the third quarter of 2001 to support a PMA submission in early 2003. Orquest is currently completing a feasibility study in the U.S., while a 140-patient study is under way in Europe to evaluate Ossigel's performance in healing fresh fractures. The company emphasizes that it is the sole developer of the product, and that it maintains a manufacturing contract with Anika Therapeutics. "The Gray Sheet" (Jan. 22, 2001, p. 15) had suggested that Ossigel is being jointly developed
You may also be interested in...
Sulzer Biologics Ne-Osteo U.S. Fusion Filing Awaits Marketing Agreement
Sulzer Biologics says it will find a U.S. distribution partner for the Ne-Osteo Spine bone morphogenic protein prior to pursuing FDA approval for use in spinal fusion.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.